Jiangsu Meishangjie Biotech Secures Tens of Millions in Series A Funding Led by Jiushong Shanhe Fund, Accelerating Entry into Class III Recombinant Collagen Implant Market

VCBeat has learned that recently,Jiangsu Meishangjie Biotechnology Co., Ltd. (hereinafter referred to as “Meishangjie”)Announced the successful completion of a Series A financing round worth tens of millions of RMB. This round of financing was led byShanghai Royal SunwardLead Investor,Zhangjiagang Jinxin CapitalandZhangjiagang City Fund Zhang Venture CapitalCo-investment injects strong momentum into MSJ’s R&D and market expansion in the field of recombinant collagen implants.

Currently, recombinant collagen accounts for 46.6% of China’s collagen market size, representing a year-on-year growth of 71.3%. The compound annual growth rate (CAGR) from 2017 to 2023 was 65.3%. It is projected that by 2027, the market size of recombinant collagen in China will reach RMB 108.3 billion, accounting for 62.3% of the total collagen market. The CAGR for the recombinant collagen market from 2024 to 2027 is expected to exceed 40%.

Amid the sustained heating up of the collagen market, a large cohort of medical aesthetics companies, represented by Giant Biogene, have successively pursued initial public offerings, while Bloomage Biotech, Jinbo Bio, and Shenguan Group have consecutively entered the fray to expand into the collagen industry.

Notably, Mr. Guan Jinsheng, founder of the Royal Sunward Shanghai Equity Investment & Fund Management Co., Ltd., is hailed as the “Godfather of China’s Securities Industry.” In 1988, he established WanGuo Securities Company, the first joint-stock securities firm in China, where he served in key leadership roles including Vice Chairman, General Manager, and President. He subsequently held positions such as Standing Director of the Shanghai Stock Exchange, Director of the Shenzhen Stock Exchange, and Standing Director of the Securities Association of China. As a distinguished figure in the financial sector, his decision to invest in MSJ not only underscores his profound insight into the promising prospects of recombinant collagen within the synthetic biology sector but also reaffirms his unique investment acumen and precise market judgment.

In the field of recombinant collagen implants, MSJ has demonstrated robust R&D capabilities and strong market competitiveness. Since its establishment in 2020, MSJ has been deeply engaged in genetic engineering and synthetic biotechnology, committed to delivering safer and more effective skincare and medical aesthetic products through technological innovation. The company initiated laboratory R&D activities in 2018 and, after two years of relentless effort, was formally established in 2020 with successful patent applications. The outstanding performance of these patents has not only garnered widespread market recognition but also earned the “2021 Excellent Invention Achievement Award” presented by the Chinese Scientists Association.

In 2022, MSJ achieved a significant breakthrough in scientific research by publishing an academic paper in the core Chinese journal "Science of Daily Chemicals," which elaborated in detail on the principles and applications of the company’s patented technologies. Currently, MSJ has launched its anti-aging skincare series and Class II medical device products. Previously, Shanxi Jinbo successfully obtained China’s first Class III medical device certification for fillers in 2022, ushering in a new era for recombinant collagen. To date, no second Class III medical device certificate has been approved in China. Leveraging its profound expertise in gene-engineered synthetic biotechnology and in-depth research into recombinant collagen implantation techniques, MSJ expects to obtain domestic Class III medical device certification for filler implants in early 2026, further solidifying its leading position in the recombinant collagen implantation sector.

Recombinant collagen, as a premium raw material, features the absence of pathogenic bacteria and endotoxin risks, along with resistance to rejection reactions. It also boasts a rational molecular weight distribution, excellent stability, and superior heat resistance. Furthermore, its sequence similarity to human collagen reaches up to 99.9%, fully demonstrating its high biocompatibility and exceptional efficacy. In the pharmaceutical industry, recombinant collagen can be used to promote wound healing in patients with deep burns, thereby accelerating recovery and reducing scar hyperplasia. In the cosmetics industry, recombinant collagen offers significant advantages in skincare applications such as skin whitening and spot reduction, repair and nourishment, and firming and wrinkle removal. Low-molecular-weight collagen provides outstanding moisturizing effects, penetrating deeply into the skin to supply essential amino acids to skin cells and repair damaged tissue. When incorporated into cosmetic formulations, recombinant collagen delivers essential nutrients to the skin and, through its abundant hydrophilic groups, imparts superior moisturizing properties, leaving the skin more hydrated and smooth.

As a highly anticipated regenerative medical aesthetic product, recombinant collagen implants are favored by consumers for their unique efficacy and safety.MSJ’s collagen, prepared via DNA recombinant technology, not only exhibits high biocompatibility and bioactivity but also allows for the design and improvement of its amino acid sequence according to specific needs, enabling customized synthesis.. This preparation method makes MSJ's recombinant collagen more comprehensive in efficacy, providing personalized solutions for different types of skin problems.

Studies have found that although the skin basement membrane is only 0.01 mm thick, it serves as a critical hub influencing skin function and is closely linked to the stratum corneum barrier. Keratinocytes originate in the basement membrane, then undergo differentiation and maturation while migrating upward to the stratum corneum, gradually forming the skin’s keratinous barrier and completing the skin’s 28-day renewal cycle. As the “adhesive” between the dermis and epidermis, damage to the basement membrane can weaken the dermal-epidermal junction, leading to skin laxity. MSJ’s recombinant collagen acts across multiple layers, spanning the epidermis and reaching deeper into the basement membrane, exerting significant regulatory effects on multiple key pathways of the basement membrane.

By promoting the production of multiple key proteins, MSJ’s recombinant collagen can significantly improve skin quality, addressing issues such as skin fragility and wrinkles. To enhance the skin’s absorption of this ingredient, MSJ precisely “trims” and processes the recombinant collagen, retaining its core efficacy while reducing its molecular weight, thereby enabling sustained penetration of collagen into the skin.

MSJ Biotechnology Co., Ltd. has achieved remarkable results in the field of gene editing, driven by its forward-looking R&D philosophy and leading technological capabilities.The company’s proprietary recombinant gene-editing technology ingeniously combines recombinant collagen with recombinant fibronectin, forming a unique microcapsule architecture.This technology not only preserves the biological activity of collagen but also enhances its permeability and stability in the skin. MSJ has developed this technology into a comprehensive technical platform with the potential to develop proteins required for various parts of the human body.

Currently,The company has successfully developed recombinant human BMP-2 protein, recombinant human GDF-11/BMP-11 protein, and recombinant metallothionein.These recombinant proteins hold broad application prospects and significant potential value in the fields of medicine and biotechnology. With the continuous advancement of science and technology and the deepening of research, they are expected to bring greater hope and possibilities for human health and disease treatment. The successful establishment of this technological platform not only demonstrates MSJ’s leading position in the biotechnology sector but also lays a solid foundation for the company’s future development.

The successful completion of this Series A financing marks a new phase in MSJ’s development in the field of recombinant collagen implants. The company will fully leverage the funds from this round to further increase its investment in R&D and market expansion, continuously enhance the core competitiveness of its products, and expand its market share. Meanwhile, MSJ will continue to uphold its philosophy of “technological innovation and quality first,” bringing consumers more safe and effective skincare and medical aesthetic products.

Looking ahead, MSJ Biotechnology Co., Ltd. will continue to deepen its expertise in the fields of genetic engineering and synthetic biology, driving technological innovation and product upgrades with the aim of becoming a renowned biotech enterprise both domestically and internationally. Meanwhile, the company will actively fulfill its social responsibilities, promote the healthy development of the industry, and deliver more high-quality skincare and medical aesthetic products to consumers, making beauty healthier and more natural.

Meanwhile, a new round of financing has been launched, with Xuyi Capital serving as the financial advisor.